UY38438A - Sales cristalinas de un inhibidor de calicreína plasmática - Google Patents

Sales cristalinas de un inhibidor de calicreína plasmática

Info

Publication number
UY38438A
UY38438A UY0001038438A UY38438A UY38438A UY 38438 A UY38438 A UY 38438A UY 0001038438 A UY0001038438 A UY 0001038438A UY 38438 A UY38438 A UY 38438A UY 38438 A UY38438 A UY 38438A
Authority
UY
Uruguay
Prior art keywords
crystalline salts
inhibitor
plasma calicrein
plasma
calicrein inhibitor
Prior art date
Application number
UY0001038438A
Other languages
English (en)
Inventor
El-Kattan Yahya
S Babu Yarlagadda
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70457981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY38438(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of UY38438A publication Critical patent/UY38438A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Sales cristalinas del Compuesto I, métodos para prepararlas y preparados farmacéuticos relacionados con las mismas. También se describen métodos de tratamiento en los que se utilizan las sales cristalinas de la invención.
UY0001038438A 2018-11-02 2019-10-31 Sales cristalinas de un inhibidor de calicreína plasmática UY38438A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862754983P 2018-11-02 2018-11-02

Publications (1)

Publication Number Publication Date
UY38438A true UY38438A (es) 2020-05-29

Family

ID=70457981

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038438A UY38438A (es) 2018-11-02 2019-10-31 Sales cristalinas de un inhibidor de calicreína plasmática

Country Status (22)

Country Link
US (11) US10662160B1 (es)
EP (1) EP3873463A4 (es)
JP (2) JP2022505670A (es)
KR (1) KR102810837B1 (es)
CN (1) CN112969458A (es)
AR (1) AR116951A1 (es)
AU (1) AU2019374115B8 (es)
BR (1) BR112021008249A2 (es)
CA (1) CA3117123A1 (es)
CL (1) CL2021001094A1 (es)
CO (1) CO2021007172A2 (es)
EA (1) EA202191192A1 (es)
IL (2) IL322896A (es)
MA (1) MA54087A (es)
MX (1) MX2021004917A (es)
PE (1) PE20211280A1 (es)
PH (1) PH12021550883A1 (es)
PY (1) PY1991831A (es)
SG (1) SG11202103804TA (es)
TW (1) TW202031255A (es)
UY (1) UY38438A (es)
WO (1) WO2020092898A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
WO2021025969A1 (en) * 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
CA2589886A1 (en) 2004-12-15 2006-06-22 Bristol-Myers Squibb Company Crystalline forms of a factor xa inhibitor
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
JP5322935B2 (ja) 2006-07-31 2013-10-23 アクティベサイト ファーマシューティカルズ インコーポレイティッド 血漿カリクレインの阻害薬
US9206146B2 (en) 2010-05-19 2015-12-08 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
KR20130105675A (ko) 2010-11-25 2013-09-25 라티오팜 게엠베하 아파티닙의 신규 염 및 다형
GB201212081D0 (en) 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
LT3113772T (lt) 2014-03-07 2020-12-28 Biocryst Pharmaceuticals, Inc. Trifluormetilo pakeistieji pirazolai kaip žmogaus plazmos kalikreino inhibitoriai
PL3355890T3 (pl) 2015-10-01 2022-02-21 Biocryst Pharmaceuticals, Inc. Inhibitory ludzkiej kalikreiny osoczowej
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
EP4010320A4 (en) 2019-08-06 2023-08-16 Biocryst Pharmaceuticals, Inc. Process-scale synthesis of a plasma kallikrein inhibitor

Also Published As

Publication number Publication date
WO2020092898A1 (en) 2020-05-07
EP3873463A1 (en) 2021-09-08
PY1991831A (es) 2020-07-03
MA54087A (fr) 2022-02-09
CO2021007172A2 (es) 2021-06-10
US20250388547A1 (en) 2025-12-25
AU2019374115B1 (en) 2025-07-17
US12552750B2 (en) 2026-02-17
US10662160B1 (en) 2020-05-26
BR112021008249A2 (pt) 2021-08-03
US12545646B2 (en) 2026-02-10
IL322896A (en) 2025-10-01
TW202031255A (zh) 2020-09-01
CN112969458A (zh) 2021-06-15
IL282454A (en) 2021-06-30
CL2021001094A1 (es) 2021-10-15
US11117867B2 (en) 2021-09-14
CA3117123A1 (en) 2020-05-07
US20250388549A1 (en) 2025-12-25
US11618733B2 (en) 2023-04-04
MX2021004917A (es) 2021-06-18
AU2019374115B8 (en) 2025-08-07
JP2022505670A (ja) 2022-01-14
KR20210087037A (ko) 2021-07-09
US20250376448A1 (en) 2025-12-11
US12590069B2 (en) 2026-03-31
US12545647B2 (en) 2026-02-10
US20250388548A1 (en) 2025-12-25
US20250388545A1 (en) 2025-12-25
US20220204454A1 (en) 2022-06-30
US20200140389A1 (en) 2020-05-07
KR102810837B1 (ko) 2025-05-20
JP2024109860A (ja) 2024-08-14
EA202191192A1 (ru) 2021-09-23
AU2019374115A1 (en) 2021-06-03
US20250376447A1 (en) 2025-12-11
PE20211280A1 (es) 2021-07-19
US12590068B2 (en) 2026-03-31
US20240109844A1 (en) 2024-04-04
EP3873463A4 (en) 2022-06-22
AR116951A1 (es) 2021-06-30
SG11202103804TA (en) 2021-05-28
US20200308118A1 (en) 2020-10-01
US20250388546A1 (en) 2025-12-25
US12545645B2 (en) 2026-02-10
PH12021550883A1 (en) 2022-02-21
US12344585B2 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2018002410A1 (es) Inhibidores de mcl-1 y métodos de uso de los mismos
ECSP18040250A (es) Composiciones y métodos para inhibir la actividad arginasa
CO2020000527A2 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
CO2021007172A2 (es) Sales cristalinas de un inhibidor de calicreína plasmática
UY37710A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
ECSP19045511A (es) Composiciones y métodos para inhibir la acción de la arginasa
ECSP19021312A (es) Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos
MX2021004593A (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana.
CL2018001899A1 (es) Salicilamidas de espiroheptanos y compuestos relacionados como inhibidores de cinasa rho (rock)
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
UY36649A (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
GT201600147A (es) Compuestos derivados y composiciones de n-azaspirocicloalcano n-heteroaril sustituido para inhibir la actividad de shp2
MX2017013797A (es) Inhibidor de janus quinasa.
MX2016013457A (es) Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo.
CO2021000049A2 (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos
EA201792021A1 (ru) Ингибитор jak
MX2018013387A (es) Inhibidores de la arginasa y sus aplicaciones terapeuticas.
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
MX2017013875A (es) Ciertos inhibidores de la proteína quinasa.
CO2020000371A2 (es) Intermedios útiles para la síntesis de un inhibidor selectivo contra proteín cinasas y procesos para preparar los mismos
SV2016005313A (es) Derivados de carboxamida
MX2018003930A (es) Inhibidores de calicreína plasmática humana.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20260218